MX2019006727A - Nuevos receptores de celulas t y terapia inmunologica que los utiliza. - Google Patents
Nuevos receptores de celulas t y terapia inmunologica que los utiliza.Info
- Publication number
- MX2019006727A MX2019006727A MX2019006727A MX2019006727A MX2019006727A MX 2019006727 A MX2019006727 A MX 2019006727A MX 2019006727 A MX2019006727 A MX 2019006727A MX 2019006727 A MX2019006727 A MX 2019006727A MX 2019006727 A MX2019006727 A MX 2019006727A
- Authority
- MX
- Mexico
- Prior art keywords
- taa
- antigen recognizing
- recognizing constructs
- novel
- tcr
- Prior art date
Links
- 108091008874 T cell receptors Proteins 0.000 title abstract 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title abstract 4
- 238000009169 immunotherapy Methods 0.000 title 1
- 239000000427 antigen Substances 0.000 abstract 4
- 108091007433 antigens Proteins 0.000 abstract 4
- 102000036639 antigens Human genes 0.000 abstract 4
- 102100025178 DDB1- and CUL4-associated factor 4-like protein 2 Human genes 0.000 abstract 2
- 101000721255 Homo sapiens DDB1- and CUL4-associated factor 4-like protein 2 Proteins 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- Hospice & Palliative Care (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
Abstract
La presente invención se relaciona con construcciones de reconocimiento de antígeno contra un antígeno asociado a tumor (TAA) derivado de la proteína blanco factor 4 asociado con DDB1 y CUL4 tipo 2 (DCAF4L2). La invención en particular provee nuevas moléculas basadas en receptores de células T (TCR) que son selectivas y especificas por el TAA de la invención. Los TCR de la invención, y los fragmentos de unión a TAA derivados de los mismos, son útiles para el diagnóstico, tratamiento y prevención de enfermedades cancerosas que expresan TAA. Además se proveen ácidos nucleicos que codifican para las construcciones de reconocimiento de antígeno de la invención, vectores que comprenden estos ácidos nucleicos, células recombinantes que expresan las construcciones de reconocimiento de antígeno y composiciones farmacéuticas que comprenden los compuestos de la invención.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662431580P | 2016-12-08 | 2016-12-08 | |
DE102016123859.7A DE102016123859B3 (de) | 2016-12-08 | 2016-12-08 | Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie |
PCT/EP2017/081893 WO2018104478A1 (en) | 2016-12-08 | 2017-12-07 | Novel t cell receptors and immune therapy using the same |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019006727A true MX2019006727A (es) | 2019-09-09 |
Family
ID=61167304
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019006727A MX2019006727A (es) | 2016-12-08 | 2017-12-07 | Nuevos receptores de celulas t y terapia inmunologica que los utiliza. |
Country Status (14)
Country | Link |
---|---|
US (3) | US10527623B2 (es) |
EP (1) | EP3551654A1 (es) |
JP (1) | JP2020511936A (es) |
KR (1) | KR20190086562A (es) |
CN (1) | CN110036027A (es) |
AU (1) | AU2017373815C1 (es) |
BR (1) | BR112019010699A2 (es) |
CA (1) | CA3045234A1 (es) |
CR (1) | CR20190276A (es) |
DE (1) | DE102016123859B3 (es) |
MX (1) | MX2019006727A (es) |
PE (1) | PE20191081A1 (es) |
TW (1) | TW201828977A (es) |
WO (1) | WO2018104478A1 (es) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11464800B2 (en) | 2018-02-09 | 2022-10-11 | Immatics US, Inc. | Methods for manufacturing T cells |
CA3097399A1 (en) * | 2018-04-19 | 2019-10-24 | The Board Of Regents, The University Of Texas System | T cell receptors with mage-b2 specificity and uses thereof |
DE102019108125B4 (de) | 2019-03-28 | 2022-02-03 | Immatics US, Inc. | Cd28 t-zellkulturen, zusammensetzungen und verfahren zu deren verwendung |
US20200297768A1 (en) | 2019-03-19 | 2020-09-24 | Immatics US, Inc. | Cd28 t cell cultures, compositions, and methods of using thereof |
CR20210669A (es) | 2019-05-27 | 2022-05-05 | Immatics Us Inc | Vectores víricos y uso de los mismos en terapias celulares adoptivas |
US20200384028A1 (en) | 2019-06-06 | 2020-12-10 | Immatics Biotechnologies Gmbh | Sorting with counter selection using sequence similar peptides |
US20220251235A1 (en) * | 2019-07-09 | 2022-08-11 | Medigene Immunotherapies Gmbh | Magea10 specific t cell receptors and their use |
AU2020319880A1 (en) * | 2019-08-01 | 2022-03-17 | The University Of North Carolina At Chapel Hill | Compositions and methods for binding antibodies and inhibiting neutralizing antibodies |
US20210032370A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
WO2021086991A1 (en) * | 2019-10-30 | 2021-05-06 | The Regents Of The University Of California | Methods of treating systemic lupus erythematosus |
AU2021225817A1 (en) | 2020-02-24 | 2022-10-20 | Immatics US, Inc. | Methods for expanding T cells for the treatment of cancer and related malignancies |
DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
CN111574616B (zh) * | 2020-06-17 | 2021-02-02 | 深圳豪石生物科技有限公司 | 分离的t细胞受体和应用 |
CN111624342A (zh) * | 2020-07-11 | 2020-09-04 | 成都益安博生物技术有限公司 | 一种卵巢癌的外周血tcr标志物及其检测试剂盒和应用 |
TW202227616A (zh) | 2020-08-21 | 2022-07-16 | 美商英麥提克斯股份有限公司 | 分離cd8+選擇t細胞的方法 |
DE102021100038A1 (de) | 2020-12-31 | 2022-06-30 | Immatics US, Inc. | Modifizierte cd8-polypeptide, zusammensetzungen und verfahren zu deren verwendung |
TW202241938A (zh) | 2020-12-31 | 2022-11-01 | 美商英麥提克斯股份有限公司 | Cd8多肽、組合物及其使用方法 |
WO2022233957A1 (en) | 2021-05-05 | 2022-11-10 | Immatics Biotechnologies Gmbh | Bma031 antigen binding polypeptides |
EP4392441A1 (en) | 2021-08-24 | 2024-07-03 | Immatics US, Inc. | Selection of immune cells using peptide mhc complexes generated by conditional ligand exchange |
WO2023044488A1 (en) | 2021-09-20 | 2023-03-23 | Immatics US, Inc. | Monocyte depletion of t cells populations for t-cell therapy |
WO2023081925A1 (en) | 2021-11-08 | 2023-05-11 | Immatics Biotechnologies Gmbh | Adoptive cell therapy combination treatment and compositions thereof |
WO2023081461A1 (en) | 2021-11-08 | 2023-05-11 | Immatics US, Inc. | Methods for generating cell spheroids |
WO2023121937A1 (en) * | 2021-12-21 | 2023-06-29 | Amgen Inc. | Dcaf4l2-specific t-cell receptors |
WO2023212691A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | DOMINANT NEGATIVE TGFβ RECEPTOR POLYPEPTIDES, CD8 POLYPEPTIDES, CELLS, COMPOSITIONS, AND METHODS OF USING THEREOF |
WO2023212655A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof |
WO2023212697A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
US20230355678A1 (en) | 2022-05-05 | 2023-11-09 | Immatics US, Inc. | Methods for improving t cell efficacy |
WO2024139780A1 (zh) * | 2022-12-26 | 2024-07-04 | 上海市第一人民医院 | 靶向巨细胞病毒pp65的T细胞受体和表达其的T细胞及应用 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
EP0814159B1 (en) | 1990-08-29 | 2005-07-27 | GenPharm International, Inc. | Transgenic mice capable of producing heterologous antibodies |
US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
EP1257289A1 (en) | 2000-02-08 | 2002-11-20 | The Penn State Research Foundation | Immunotherapy using interleukin 13 receptor subunit alpha 2 |
EP2660250B1 (en) * | 2012-05-02 | 2018-11-14 | Deutsches Rheuma-Forschungszentrum Berlin | Tcr transgenic mouse model for immune disease |
EP3636665B1 (en) * | 2012-09-14 | 2022-06-29 | The United States of America, as represented by The Secretary, Department of Health and Human Services | T cell receptors recognizing mhc class ii-restricted mage-a3 |
EP3572510B1 (en) * | 2013-11-21 | 2022-09-21 | Repertoire Genesis Incorporation | T cell receptor and b cell receptor repertoire analysis system, and use of same in treatment and diagnosis |
KR20170032406A (ko) * | 2014-07-15 | 2017-03-22 | 주노 쎄러퓨티크스 인코퍼레이티드 | 입양 세포 치료를 위한 조작된 세포 |
CN105506065A (zh) * | 2014-09-25 | 2016-04-20 | 上海人类基因组研究中心 | 肝癌基因检测方法、检测试剂盒及其应用 |
GB201505305D0 (en) * | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
GB201520583D0 (en) * | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
-
2016
- 2016-12-08 DE DE102016123859.7A patent/DE102016123859B3/de not_active Expired - Fee Related
-
2017
- 2017-12-07 CA CA3045234A patent/CA3045234A1/en not_active Abandoned
- 2017-12-07 AU AU2017373815A patent/AU2017373815C1/en not_active Ceased
- 2017-12-07 CR CR20190276A patent/CR20190276A/es unknown
- 2017-12-07 MX MX2019006727A patent/MX2019006727A/es unknown
- 2017-12-07 US US15/835,095 patent/US10527623B2/en not_active Expired - Fee Related
- 2017-12-07 KR KR1020197019008A patent/KR20190086562A/ko active IP Right Grant
- 2017-12-07 EP EP17825768.9A patent/EP3551654A1/en not_active Withdrawn
- 2017-12-07 BR BR112019010699A patent/BR112019010699A2/pt not_active IP Right Cessation
- 2017-12-07 PE PE2019001096A patent/PE20191081A1/es unknown
- 2017-12-07 CN CN201780075298.4A patent/CN110036027A/zh active Pending
- 2017-12-07 JP JP2019528908A patent/JP2020511936A/ja active Pending
- 2017-12-07 WO PCT/EP2017/081893 patent/WO2018104478A1/en unknown
- 2017-12-08 TW TW106143135A patent/TW201828977A/zh unknown
-
2018
- 2018-07-02 US US16/025,434 patent/US10725044B2/en not_active Expired - Fee Related
-
2020
- 2020-03-24 US US16/828,577 patent/US20200249233A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2017373815C1 (en) | 2021-08-26 |
US10527623B2 (en) | 2020-01-07 |
JP2020511936A (ja) | 2020-04-23 |
US20200249233A1 (en) | 2020-08-06 |
TW201828977A (zh) | 2018-08-16 |
CA3045234A1 (en) | 2018-06-14 |
WO2018104478A1 (en) | 2018-06-14 |
US20180306789A1 (en) | 2018-10-25 |
CR20190276A (es) | 2019-10-30 |
DE102016123859B3 (de) | 2018-03-01 |
CN110036027A (zh) | 2019-07-19 |
KR20190086562A (ko) | 2019-07-22 |
US20180164315A1 (en) | 2018-06-14 |
US10725044B2 (en) | 2020-07-28 |
EP3551654A1 (en) | 2019-10-16 |
PE20191081A1 (es) | 2019-08-20 |
AU2017373815A1 (en) | 2019-06-27 |
AU2017373815B2 (en) | 2020-12-10 |
BR112019010699A2 (pt) | 2019-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019006727A (es) | Nuevos receptores de celulas t y terapia inmunologica que los utiliza. | |
MX2022015821A (es) | Nuevos receptores de celulas t y usos de los mismos. | |
MX2019006724A (es) | Nuevos receptores de celulas t y terapia inmunologica que los utiliza. | |
MX2019001769A (es) | Nuevos receptores de linfocitos t e inmunoterapia basada en el uso de los mismos. | |
PH12020550600A1 (en) | Novel engineered t cell receptors and immune therapy using the same | |
MX2023003463A (es) | Receptores de linfocitos t e inmunoterapias basadas en el uso de los mismos contra canceres positivos para prame. | |
WO2018172533A3 (en) | T cell receptors and immune therapy using the same against prame positive cancers | |
PH12019500312A1 (en) | T cell receptors and immune therapy using the same | |
MX2019015742A (es) | Receptores de celulas t novedosos, e inmunoterapia usando los mismos. | |
MX2020001996A (es) | Moleculas anti-cd137 y uso de estas. | |
JOP20200313A1 (ar) | أجسام مضادة dll3-cd3 ثنائية الخاصية | |
MX2019006045A (es) | Proteinas triespecificas dirigidas a psma y metodos de uso. | |
MX2018010824A (es) | Proteinas de union inducibles y metodos de uso. | |
PH12019500122A1 (en) | Bispecific antibody-like binding proteins specifically binding to cd3 and cd123 | |
MX2017014908A (es) | Proteinas de union triespecificas y metodos de uso. | |
EA202191027A3 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии нескольких видов опухолей | |
PH12019500571A1 (en) | Anti-pd-1 antibodies | |
WO2020076977A3 (en) | Dll3 single domain antibodies and therapeutic compositions thereof | |
MX2020001287A (es) | Receptor de linfocitos t (tcrs) especificos de braf y usos de los mismos. | |
PH12019501263A1 (en) | Novel t cell receptors and immune therapy using the same | |
NZ750479A (en) | T cell receptors and immune therapy using the same | |
EA202090712A1 (ru) | Новые полученные методами генной инженерии t-клеточные рецепторы и иммунная терапия с их использованием | |
EA201991139A1 (ru) | Новые т-клеточные рецепторы и иммунотерапия с их применением | |
EA201992002A1 (ru) | Т-клеточные рецепторы и иммунная терапия prame-положительных раковых заболеваний с их применением | |
AR110682A1 (es) | Receptores de células t y terapia inmunológica que los utiliza |